12:00 AM
 | 
Oct 14, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Kadcyla trastuzumab emtansine: Additional Phase III data

Additional data from the open-label, international Phase III TH3RESA trial in 600 patients with HER2-positive metastatic breast cancer who have progressed on HER2-targeted treatment showed that IV Kadcyla as third-line treatment led to a median PFS, the co-primary endpoint, of 6.2 months vs. 3.3 months for physician's choice of therapy (p<0.0001). Data for the co-primary endpoint of OS are not yet mature, with only 21% of targeted events observed. Interim median OS was 14.9 months in the physician's choice group and has...

Read the full 387 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >